Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Division of Cardiovascular Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Int J Artif Organs. 2024 Jun;47(6):401-410. doi: 10.1177/03913988241254978. Epub 2024 Jun 10.
A feared complication of an acute myocardial infarction (AMI) is cardiac arrest (CA). Even if return of spontaneous circulation is achieved, cardiogenic shock (CS) is common. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) supports patients with CS and is often used in conjunction with an Impella device (2.5 and CP) to off-load the left ventricle, although limited evidence supports this approach.
The goal of this study was to determine whether a mortality difference was observed in VA-ECMO alone versus VA-ECMO with Impella (ECPELLA) in patients with CS from AMI and CA. A retrospective chart review of 50 patients with AMI-CS and CA and were supported with VA-ECMO ( = 34) or ECPELLA ( = 16) was performed. The primary outcome was all-cause mortality at 6-months from VA-ECMO or Impella implantation. Secondary outcomes included in-hospital mortality and complication rates between both cohorts and intensive care unit data.
Baseline characteristics were similar, except patients with ST-elevation myocardial infarction were more likely to be in the VA-ECMO group ( = 0.044). The ECPELLA cohort had significantly worse survival after VA-ECMO (SAVE) score ( = 0.032). Six-month all-cause mortality was not significantly different between the cohorts, even when adjusting for SAVE score. Secondary outcomes were notable for an increased rate of minor complications without an increased rate of major complications in the ECPELLA group.
Randomized trials are needed to determine if a mortality difference exists between VA-ECMO and ECPELLA platforms in patients with AMI complicated by CA and CS.
急性心肌梗死(AMI)的一种可怕并发症是心脏骤停(CA)。即使自主循环恢复,心源性休克(CS)也很常见。静脉动脉体外膜肺氧合(VA-ECMO)支持 CS 患者,并且经常与 Impella 设备(2.5 和 CP)一起使用以减轻左心室的负荷,尽管有限的证据支持这种方法。
本研究的目的是确定在 AMI 合并 CA 并接受 VA-ECMO(n=34)或 ECPELLA(n=16)支持的 CS 患者中,单独使用 VA-ECMO 与使用 VA-ECMO 加 Impella(ECPELLA)是否存在死亡率差异。对 50 例 AMI-CS 和 CA 患者进行回顾性图表审查,并接受 VA-ECMO 或 ECPELLA 支持。主要结局是从 VA-ECMO 或 Impella 植入后 6 个月的全因死亡率。次要结局包括两组患者的院内死亡率和并发症发生率以及重症监护病房数据。
基线特征相似,但 ST 段抬高型心肌梗死患者更可能在 VA-ECMO 组(n=0.044)。ECPELLA 组 VA-ECMO 后 SAVE 评分(n=0.032)显著较差。即使在校正 SAVE 评分后,两组之间 6 个月的全因死亡率也无显著差异。次要结局值得注意的是,ECPELLA 组 minor 并发症的发生率增加,但 major 并发症的发生率没有增加。
需要进行随机试验来确定在 AMI 合并 CA 和 CS 的患者中,VA-ECMO 和 ECPELLA 平台之间是否存在死亡率差异。